<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972829</url>
  </required_header>
  <id_info>
    <org_study_id>BAR-09-07</org_study_id>
    <nct_id>NCT00972829</nct_id>
  </id_info>
  <brief_title>Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bronx VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bronx VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, research studies have shown that patients who have had trouble taking statins every&#xD;
      day, are able to take statins if they take them only once or twice a week. The investigators&#xD;
      are doing a research study which involves switching people who are taking ezetimibe to the&#xD;
      statin Crestor once or twice a week and to see how ell Crestor lowers cholesterol and if it&#xD;
      is tolerated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Low-density lipoprotein (LDL) cholesterol</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Low-density lipoprotein (LDL) cholesterol</measure>
    <time_frame>3-4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ability to remain on Crestor for the study period</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Crestor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crestor 10 or 20 milligrams</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ezetimibe 5 or 10 milligrams</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 10 or 20 milligrams once or twice a week</description>
    <arm_group_label>Crestor</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe 5 or 10 milligrams</description>
    <arm_group_label>Ezetimibe</arm_group_label>
    <other_name>Zetia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of intolerance to statins&#xD;
&#xD;
          -  Patients currently receiving ezetimibe&#xD;
&#xD;
          -  Patients willing and able to provide signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving a statin (Lipitor, Crestor, Lescol, Simvastatin, or Pravachol)&#xD;
&#xD;
          -  Stroke, TIA, myocardial infarction, unstable angina, percutaneous coronary&#xD;
             intervention, coronary artery bypass surgery, or major surgery within 3 months&#xD;
&#xD;
          -  Cancer undergoing active treatment&#xD;
&#xD;
          -  Creatinine clearance &lt; 40 ml/minute&#xD;
&#xD;
          -  Active liver disease or persistent elevation of SGOT or SGPT &gt; 2 times the upper limit&#xD;
             of normal level&#xD;
&#xD;
          -  Participation in any clinical study within the last 30 days&#xD;
&#xD;
          -  Drug addition or alcohol abuse within the past 6 months&#xD;
&#xD;
          -  Use of cyclosporine within the last 3 months&#xD;
&#xD;
          -  Use of gemfibrozil within the last month&#xD;
&#xD;
          -  Patients unwilling or unable to provide informed consent&#xD;
&#xD;
          -  Patients with poor compliance&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  History of rhabdomyolysis due to statins&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Baruch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James J.Peters VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bronx VA Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Baruch, MD</last_name>
      <phone>718-584-9000</phone>
      <phone_ext>5970</phone_ext>
      <email>lawrence.baruch@va.gov</email>
    </contact>
    <investigator>
      <last_name>Lawrence Baruch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>September 9, 2009</last_update_submitted>
  <last_update_submitted_qc>September 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Lawrence Baruch, MD</name_title>
    <organization>James J. Peters VA Medical Center</organization>
  </responsible_party>
  <keyword>Hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

